Caveolin-1 as a target in prevention and treatment of hypertrophic scarring

Ilja L. Kruglikov; Philipp E. Scherer

doi:10.1038/s41536-019-0071-x

Caveolin-1 as a target in prevention and treatment of hypertrophic scarring

Ilja L. Kruglikov, Philipp E. Scherer

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Abstract

Reduced expression of caveolin-1 (Cav-1) is an important pathogenic factor in hypertrophic scarring (HTS). Such a reduction can be found in connection with the main known risk factors for HTS, including dark skin, female gender, young age, burn site and severity of the injury. The degree of overexpression of Cav-1 associated with different therapeutic options for HTS correlates with clinical improvements in HTS. This makes endo- or exogenous induction of Cav-1 not only an important therapeutic target for HTS, but also highlights its use as a preventive target to reduce or avoid HTS formation.

Original language	English (US)
Article number	9
Journal	npj Regenerative Medicine
Volume	4
Issue number	1
DOIs	https://doi.org/10.1038/s41536-019-0071-x
State	Published - Dec 1 2019

ASJC Scopus subject areas

Biomedical Engineering
Cell Biology
Developmental Biology
Medicine (miscellaneous)

Access to Document

10.1038/s41536-019-0071-x

Cite this

@article{e6e7bc85e29a494fadeb177be54437d7,

title = "Caveolin-1 as a target in prevention and treatment of hypertrophic scarring",

abstract = "Reduced expression of caveolin-1 (Cav-1) is an important pathogenic factor in hypertrophic scarring (HTS). Such a reduction can be found in connection with the main known risk factors for HTS, including dark skin, female gender, young age, burn site and severity of the injury. The degree of overexpression of Cav-1 associated with different therapeutic options for HTS correlates with clinical improvements in HTS. This makes endo- or exogenous induction of Cav-1 not only an important therapeutic target for HTS, but also highlights its use as a preventive target to reduce or avoid HTS formation.",

author = "Kruglikov, {Ilja L.} and Scherer, {Philipp E.}",

note = "Publisher Copyright: {\textcopyright} 2019, The Author(s).",

year = "2019",

month = dec,

day = "1",

doi = "10.1038/s41536-019-0071-x",

language = "English (US)",

volume = "4",

journal = "npj Regenerative Medicine",

issn = "2057-3995",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Caveolin-1 as a target in prevention and treatment of hypertrophic scarring

AU - Kruglikov, Ilja L.

AU - Scherer, Philipp E.

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Reduced expression of caveolin-1 (Cav-1) is an important pathogenic factor in hypertrophic scarring (HTS). Such a reduction can be found in connection with the main known risk factors for HTS, including dark skin, female gender, young age, burn site and severity of the injury. The degree of overexpression of Cav-1 associated with different therapeutic options for HTS correlates with clinical improvements in HTS. This makes endo- or exogenous induction of Cav-1 not only an important therapeutic target for HTS, but also highlights its use as a preventive target to reduce or avoid HTS formation.

AB - Reduced expression of caveolin-1 (Cav-1) is an important pathogenic factor in hypertrophic scarring (HTS). Such a reduction can be found in connection with the main known risk factors for HTS, including dark skin, female gender, young age, burn site and severity of the injury. The degree of overexpression of Cav-1 associated with different therapeutic options for HTS correlates with clinical improvements in HTS. This makes endo- or exogenous induction of Cav-1 not only an important therapeutic target for HTS, but also highlights its use as a preventive target to reduce or avoid HTS formation.

UR - http://www.scopus.com/inward/record.url?scp=85071972498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071972498&partnerID=8YFLogxK

U2 - 10.1038/s41536-019-0071-x

DO - 10.1038/s41536-019-0071-x

M3 - Article

C2 - 31044089

AN - SCOPUS:85071972498

SN - 2057-3995

VL - 4

JO - npj Regenerative Medicine

JF - npj Regenerative Medicine

IS - 1

M1 - 9

ER -

Caveolin-1 as a target in prevention and treatment of hypertrophic scarring

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this